Answers are grounded in this paper and cite their sources.
Outlines clinical management strategies for thrombosis and pregnancy complications in antiphospholipid syndrome, highlighting modern evidence from general thromboprophylaxis trials.
This article discusses how we approach medical decision making in the treatment of the various facets of the antiphospholipid syndrome (APS), including secondary prophylaxis in the setting of venous and arterial thrombosis, as well as treatment for the prevention of recurrent miscarriages and fetal death. The role of primary thromboprophylaxis is also discussed in depth. Great emphasis is given to incorporating the most up-to-date and relevant evidence base both from the APS literature, and from large, recent, randomized controlled trials (RCTs) of primary and secondary thrombotic prophylaxis in the general population setting (ie, the population that has not been specifically investigated for APS).
No takes yet. Share an insight, caveat, or question.
Giannakopoulos et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: